GSK to Supply U.S. Government with Anthrax Treatment


Sep 20, 2013

GlaxoSmithKline and the Biomedical Advanced Research and Development Authority, part of the U.S. government, signed a contract for anthrax treatment. Sheri Mullen, vice president of Immunology & Rare Diseases, U.S. Pharmaceuticals, GSK, said the four-year agreement calls for the provision of its inhalation anthrax treatment, raxibacumab. Read the full story

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.


No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments